These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31111305)

  • 1. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.
    Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L
    AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.
    Le Merdy M; Tan ML; Babiskin A; Zhao L
    AAPS J; 2020 Jan; 22(2):26. PubMed ID: 31907674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.
    Le Merdy M; Spires J; Lukacova V; Tan ML; Babiskin A; Xu X; Zhao L; Bolger MB
    Pharm Res; 2020 Nov; 37(12):245. PubMed ID: 33215336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceutics of Topical Ophthalmic Suspensions: Importance of Viscosity and Particle Size in Ocular Absorption of Indomethacin.
    Toropainen E; Fraser-Miller SJ; Novakovic D; Del Amo EM; Vellonen KS; Ruponen M; Viitala T; Korhonen O; Auriola S; Hellinen L; Reinisalo M; Tengvall U; Choi S; Absar M; Strachan C; Urtti A
    Pharmaceutics; 2021 Mar; 13(4):. PubMed ID: 33810564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.
    Deng F; Ranta VP; Kidron H; Urtti A
    Pharm Res; 2016 Nov; 33(11):2680-90. PubMed ID: 27431864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension.
    Scoper SV; Kabat AG; Owen GR; Stroman DW; Kabra BP; Faulkner R; Kulshreshtha AK; Rusk C; Bell B; Jamison T; Bernal-Perez LF; Brooks AC; Nguyen VA
    Adv Ther; 2008 Feb; 25(2):77-88. PubMed ID: 18309465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
    Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
    Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical pharmacokinetics of dexamethasone suspensions in the rabbit eye: Bioavailability comparison.
    Naageshwaran V; Ranta VP; Toropainen E; Tuomainen M; Gum G; Xie E; Bhoopathy S; Urtti A; Del Amo EM
    Int J Pharm; 2022 Mar; 615():121515. PubMed ID: 35091006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for evaluation of topical ophthalmic drug products in different compartments of fresh eye tissues in a rabbit model.
    Chockalingam A; Xu L; Stewart S; LeMerdy M; Tsakalozou E; Fan J; Patel V; Rouse R
    J Pharmacol Toxicol Methods; 2019; 96():9-14. PubMed ID: 30552958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
    Fialho SL; da Silva-Cunha A
    Clin Exp Ophthalmol; 2004 Dec; 32(6):626-32. PubMed ID: 15575833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation.
    Kesavan K; Kant S; Singh PN; Pandit JK
    Curr Eye Res; 2013 Mar; 38(3):342-52. PubMed ID: 23216079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits.
    Schoenwald RD; Stewart P
    J Pharm Sci; 1980 Apr; 69(4):391-4. PubMed ID: 7373531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of particle dissolution rate on ocular drug bioavailability.
    Hui HW; Robinson JR
    J Pharm Sci; 1986 Mar; 75(3):280-7. PubMed ID: 3701612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding dexamethasone kinetics in the rabbit tear fluid: Drug release and clearance from solution, suspension and hydrogel formulations.
    Balla A; Ruponen M; Valtari A; Toropainen E; Tuomainen M; Alvarez-Lorenzo C; Del Amo EM; Urtti A; Vellonen KS
    Eur J Pharm Biopharm; 2022 Mar; 172():53-60. PubMed ID: 35121080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic prediction of the ocular absorption of an instilled drug with ophthalmic viscous vehicle.
    Sasaki H; Yamamura K; Mukai T; Nishida K; Nakamura J; Nakashima M; Ichikawa M
    Biol Pharm Bull; 2000 Nov; 23(11):1352-6. PubMed ID: 11085365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation.
    Le Merdy M; AlQaraghuli F; Tan ML; Walenga R; Babiskin A; Zhao L; Lukacova V
    Pharm Res; 2023 Feb; 40(2):431-447. PubMed ID: 36151444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutical considerations in topical ocular drug delivery.
    Davies NM
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):558-62. PubMed ID: 10874518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.